Pharmaceutical Lobby Sues Over Trump Admin Drug Pricing Program

Merck: Merck is a leading global pharmaceutical company engaged in the research and production of prescription medicines and vaccines. It is among the manufacturers represented by PhRMA and has reached agreements on drug pricing with the current administration. Pfizer: Pfizer is a major global pharmaceutical company focused on the discovery, development, and manufacturing of prescription medicines. The company is represented by PhRMA in the lawsuit and has entered into pricing agreements with the Trump administration. Stephen Ubl: Stephen Ubl serves as president and CEO of the Pharmaceutical Research and Manufacturers of America. He issued a statement on behalf of the organization criticizing the most-favored-nation policy as unlawful and likely to harm medical innovation and patient access. GlaxoSmithKline: GlaxoSmithKline is a multinational pharmaceutical and biotechnology company that develops and manufactures medicines and vaccines. The firm is represented by PhRMA in the ongoing litigation and has agreed to pricing terms with the Trump administration. Center for Medicare & Medicaid Services: The Center for Medicare & Medicaid Services (CMS) is the federal agency within the Department of Health and Human Services that administers the Medicare and Medicaid programs. CMS is developing and planning to implement the most-favored-nation pricing model for certain drugs under Medicare, which has prompted the current legal challenge from industry groups. Department of Health and Human Services: The Department of Health and Human Services (HHS) is the cabinet-level federal agency responsible for protecting public health and providing essential human services, including oversight of Medicare and Medicaid through its subsidiary CMS. HHS is named as a defendant in the lawsuit filed by PhRMA over the drug pricing program. Pharmaceutical Research and Manufacturers of America: The Pharmaceutical Research and Manufacturers of America (PhRMA) is a trade association representing leading research-based pharmaceutical and biotechnology companies in the United States. In this development, PhRMA filed a federal lawsuit on October 7 challenging a most-favored-nation drug pricing policy for Medicare, arguing that it exceeds statutory authority and imports foreign price controls. Prior Legal Action: PhRMA previously challenged an earlier version of the most-favored-nation policy during the first Trump administration, resulting in a temporary restraining order before the rule was later withdrawn. Policy Implementation: The most-favored-nation pricing effort updates Medicare's drug pricing model to base payments on average sales prices from multiple nations. Administration Agreements: The Trump administration has reached drug pricing agreements with multiple manufacturers including Pfizer, Merck, and GlaxoSmithKline.